Navigation Links
ReportsnReports: Depression Therapeutics Market to Reach $10.9 Billion by 2018
Date:10/17/2011

eline candidates fall under major therapeutic classes such as Glutamate receptor which includes Metabotropic glutamate receptors 2 antagonist, Glutamate receptor 2 and 3 antagonist, Group II metabotropic glutamate receptors antagonist, Metabotropic glutamate receptor 5 antagonist, N-methyl d-aspartate receptor (NMDAR) antagonist, Alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) potentiator whereas Seretonin receptor modulators which includes 5-HT3, 5-HT7 and 5-HT1A receptor receptor agonist and 5-HT transporter inhibitor, 5-HT3 and 5-HT2C antagonist, 5HT reuptake blockade, 5HT2 agonism, 5HT1A agonism, and 5HT1D central receptors agonist, 5-HT2A/5-HT2C/D2/D3 receptor antagonist followed by Triple-reuptake inhibitors, Monoamine oxidase (MAO) modulators, Arginine vasopressin antagonists and so on.
  • Analysis of the current and future competition in the global depression market. Key market players covered are Otsuka Holdings Co., Ltd, Forest Laboratories, H Lundbeck A/s, Eli Lilly, Targacept Inc., Fabre-Kramer Pharmaceuticals, Inc., Euthymics Bioscience, Inc., AstraZeneca PLC, and Novartis/Servier.
  • An insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
  • Key topics covered include a strategic competitor assessment, market characterization, unmet needs and the implications for the depression therapeutics market.
  • Analysis of key recent licensing and partnership agreements in the depression therapeutics market.

  • Reasons to buy

    The report will enhance your decision making capabilities. It will allow you to:

    • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipelines.
    • Develop business strategies by understanding th
      '/>"/>

    SOURCE ReportsnReports
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Ridge Diagnostics, Inc. Clinical Data on Blood Test for Depression to be Presented at the American Psychiatric Association Annual Meeting
    2. Ridge Diagnostics, Inc. Presents Clinical Data on Blood Test for Depression at U.S. Psychiatric and Mental Health Congress
    3. Orexigen(R) Therapeutics Announces That Contrave(R) Reduced Depression Scores and Body Weight in Overweight and Obese Patients With Major Depression
    4. Cancer, Heart Disease, Stroke, Diabetes, Chronic Pain and Depression Share a Major Pathology Factor
    5. ECG for the mind could diagnose depression in an hour
    6. REMERON(R) Now Approved in Japan for the Treatment of Depression in Adult Patients
    7. Psylin Neurosciences Commences Development of Compound for Depression
    8. Cyberonics Provides Business Update on Depression Clinical Trial
    9. FDA Approves AstraZenecas SEROQUEL XR(R) for the Treatment of Bipolar Depression and Bipolar Mania
    10. Shield Therapeutics Initiates AEGIS 1 and AEGIS 2 Phase 3 Studies of ST10
    11. United Therapeutics Announces Proposed Private Offering of $210 Million of Convertible Senior Notes and Authorization of Stock Repurchase Program
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:8/21/2014)... (PRWEB) August 21, 2014 DNA vaccine ... progress in its development of JRC-LAMP-vax, an innovative and ... pollen. Phase IC studies began this month in Hawaii, ... hay fever. , The Japanese red cedar releases pollen ... in Japan. Mountain Cedar pollen wreaks similar havoc in ...
    (Date:8/21/2014)... His Majesty Willem-Alexander, King of the ... of His Majesty Willem-Alexander, King of the Netherlands, has ... of POET-DSM Advanced Biofuels’ Project LIBERTY cellulosic ethanol plant ... King will take part in the Grand Opening Ceremony ... a.m.-12:20 p.m. and tour the plant. POET-DSM is a ...
    (Date:8/21/2014)... Aug. 21, 2014 OTC Markets ... Inc., a biotechnology company, on its approval to ... traded on OTCQX®, the best marketplace for established ... Group. Logo - http://photos.prnewswire.com/prnh/20110118/MM31963LOGO ... successful execution of its growth strategy and achievement ...
    (Date:8/21/2014)... MO (PRWEB) August 21, 2014 ... service biopharmaceutical contract development and manufacturing organization (CMO) ... Progenics Pharmaceuticals, Inc., an oncology company focused on ... treating cancer, to manufacture the anti-prostate specific membrane ... ADC product candidate. Under the agreement the ...
    Breaking Biology Technology:Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 2Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 3Relief for Allergy Sufferers Finally in Sight: Immunomic Therapeutics Closes in on Treatment for Hay Fever in Japan, U.S. 4His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 2His Majesty Willem-Alexander, King of the Netherlands, to Attend Project LIBERTY opening 3OTC Markets Group Congratulates Immune Pharmaceuticals on NASDAQ Listing 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3
    ... -- PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, announced today that its financial ... released on Thursday, May 14, 2009.PharmAthene management will be ... 2009 financial results. The call is scheduled to ...
    ... Pharmaceuticals, Inc. (Nasdaq: OPTR ) today announced its financial ... a net loss for the first quarter of 2009 of $10.9 ... Company,s expectations. This compares to a net loss for the ... Research and development expenses in the first quarter of 2009 ...
    ... DNDN ) today announced that management will present at the ... Merrill Lynch 2009 Health Care Conference, The New York ... 9:20 a.m. ET, Deutsche Bank Securities 34th Annual Healthcare ... 2009, 4:35 p.m. ET, Leerink Swann ...
    Cached Biology Technology:Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 2Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 3Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 4Optimer Pharmaceuticals Reports First Quarter 2009 Financial Results 5
    (Date:8/21/2014)... LAWRENCE A study recently published in the journal ... Kansas shows a new role for the protein adenomatous ... second-leading cause of cancer-related deaths in the U.S. , ... of Molecular Biosciences and co-leader of the Cancer Biology ... better part of her career trying to understand the ...
    (Date:8/21/2014)... A team of researchers at Louisiana Tech ... using affordable, consumer-grade 3D printers and materials ... contain antibacterial and chemotherapeutic compounds for targeted ... doctoral students and research faculty from Louisiana ... collaborated to create filament extruders that can ...
    (Date:8/21/2014)... developed a novel and versatile modeling strategy to simulate ... materials as well as for studying polyelectrolytes, including DNA ... model much larger and more complex polyelectrolyte systems, and ... lead author of a paper on the work and ... Science and Engineering. "This is a big step forward ...
    Breaking Biology News(10 mins):Research offers insight into cellular biology of colorectal cancer 2Research offers insight into cellular biology of colorectal cancer 3Louisiana Tech University researchers use 3D printers to create custom medical implants 2Louisiana Tech University researchers use 3D printers to create custom medical implants 3Researchers develop models to study polyelectrolytes, including DNA and RNA 2
    ... liver disease, extent of tissue damage depends on the balance ... new liver cells. In a significant minority of people who ... form scars. This can progress to chronic liver disease and ... unable to clean blood or produce vital hormones and clotting ...
    ... a type of cell that can be activated by tissues ... attack our own molecules, cells and organs, UCSF researchers have ... new strategies for fighting a range of autoimmune diseases ... and cells within us as well as for preventing ...
    ... CHICAGO A low-calorie diet eliminates insulin dependence ... with type 2 diabetes, according to a study presented ... of North America (RSNA). "Lifestyle interventions may have ... patients," said the study,s lead author, Sebastiaan Hammer, M.D., ...
    Cached Biology News:The immune system has protective memory cells, researchers discover 2The immune system has protective memory cells, researchers discover 3Restricted calorie diet improves heart function in obese patients with diabetes 2
    ... The Label IT siRNA Tracker ... Reagent provides a straight forward approach ... of your design, in an efficient ... tracking experiments. Subcellular localization and functional ...
    ... (A) and 36kDa (C) subunits Formulation: ... 500mM NaCl, 60mM 2-mercaptoethanol, 1mM MgCl2, ... and 0.1mg/ml serum albumin Properites: For ... Purification: DEAE chromatography, aminohexyl-agarose and gel ...
    ... IT siRNA Tracker Intracellular Localization Kit ... straight forward approach to directly label ... in an efficient yet non-destructive manner, ... localization and functional inhibition of target ...
    ... The Label IT siRNA Tracker Intracellular ... provides a straight forward approach to ... your design, in an efficient yet ... experiments. Subcellular localization and functional inhibition ...
    Biology Products: